BioSpace News Archive

Pixelgen Technologies emerged from stealth today with a mission to bring a new dimension to single-cell spatial proteomics.

Generate Biomedicines today announced that it has published data in the peer-reviewed journal Frontiers in Immunology that demonstrate the power of the company’s technology platform to generate re-surfaced proteins, which may provide a means to creating novel therapies for diseases with limited therapeutic options.

According to Nova one advisor, the global Bioprocess Technology market size is expected to hit around USD 53.30 billion by 2030 from valued at USD 23.45 billion in 2021 and growing at a CAGR of 9.7% from 2022 to 2030.

According to Nova one advisor, the global Psoriatic Arthritis Therapeutics market size was exhibited at USD 12.8 billion in 2022 and is projected to hit around USD 30.2 billion by 2032, growing at a CAGR of 9.70% during the forecast period 2023 to 2032.

Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in oncology, neurology, and virology today announced its intention to study the potential therapeutic use of its investigational COVID-19 T cell therapy, TVGN-489, in immunocompromised patients.

Hoag’s innovative spine team has performed the first spinal fusion surgery utilizing the recently FDA-cleared augmented reality surgical navigator for Spine, co-developed by neurosurgeons from Hoag’s Pickup Family Neurosciences Institute and medical visualization platform leader Surgical Theater.

City of Hope announced it has received, along with other leading cancer centers, an $8 million Therapy ACceleration To Intercept CAncer Lethality award from the Prostate Cancer Foundation to develop clinic-ready chimeric antigen receptor T cell therapies for advanced prostate cancer that can overcome the therapy’s current limitations.

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that an abstract relating to its ongoing Phase 2 myelofibrosis trial (MYLOX-1) has been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting.

Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company’s rights offering as previously announced on November 29, 2022.

Nurix Therapeutics, Inc. announced that it will host a live webcast to review clinical data from the Phase 1 clinical trial of its leading BTK degrader program, NX-2127, at 8:30 pm CT on Monday, December 12, 2022.